Novavax (NVAX) Reports Q3 Loss of $3.21/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Novavax Reports Third Quarter 2020 Financial and Operational Results
November 9, 2020 4:06 PM ESTAdvanced clinical development of NVXCoV2373 with initiation of first Phase 3 trial to evaluate efficacy, safety and immunogenicityU.K. Phase 3 interim data expected as soon as early first quarter 2021Secured additional large-scale manufacturing for NVX-CoV2373 with expected global capacity over two billion doses by mid-2021Formed leadership team to advance NanoFlu through global licensureCompany to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for... More
